Checkpoint Receptor Agonist (Radiant Biotherapeutics)

The Checkpoint Receptor Agonist program by Radiant Biotherapeutics is a preclinical-stage therapeutic initiative focused on developing multi-specific engineered molecules using the proprietary Multabody™ platform. These molecules are designed to act as agonists for unspecified immune checkpoint receptors, aiming to modulate and potentially suppress overactive immune or inflammatory responses. This approach is intended for the treatment of various immunological and inflammatory disorders, representing a therapeutic strategy that contrasts with the checkpoint antagonism commonly employed in oncology. The Multabody™ platform allows for the creation of molecules with high valency and multi-specificity, which may enhance the potency and selectivity of immune modulation compared to traditional monoclonal antibodies.

Other names

Checkpoint Receptor AgonistRadiant Biotherapeutics Checkpoint Receptor Agonist program